Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors, has announced its participation in two upcoming investor conferences in March 2025.
CEO Elisabet de los Pinos will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 9:10 a.m. ET. She will also attend the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, with a fireside chat scheduled for 8:00 a.m. ET.
Live webcasts of both presentations will be available on the "Investors & Media" page under the "Events & Presentations" section of Aura's website. Replays will remain accessible for 90 days following each presentation.
Aura Biosciences (NASDAQ: AURA), une entreprise de biotechnologie en phase clinique développant des thérapies de précision pour les tumeurs solides, a annoncé sa participation à deux prochaines conférences pour investisseurs en mars 2025.
La PDG Elisabet de los Pinos participera à un fireside chat lors de la TD Cowen 45th Annual Health Care Conference le mardi 4 mars 2025, à 9h10 ET. Elle assistera également à la Leerink Partners Global Healthcare Conference le mardi 11 mars 2025, avec un fireside chat prévu pour 8h00 ET.
Des webcasts en direct des deux présentations seront disponibles sur la page
- None.
- None.
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
- TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.
Fireside Chat at 9:10 a.m. ET. - Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025.
Fireside Chat at 8:00 a.m. ET.
The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
FAQ
When will Aura Biosciences (AURA) present at the TD Cowen Health Care Conference in March 2025?
What investor conferences is Aura Biosciences (AURA) attending in March 2025?
How can investors access Aura Biosciences' (AURA) conference presentations in March 2025?
What time is Aura Biosciences' (AURA) presentation at the Leerink Partners Conference in March 2025?
Who will represent Aura Biosciences (AURA) at the March 2025 investor conferences?
